Vaxcyte, Inc.
Clinical trials sponsored by Vaxcyte, Inc., explained in plain language.
Vaxcyte, Inc.
PCVX
NASDAQ
A biopharmaceutical company developing vaccines to prevent bacterial infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New vaccine aims to outsmart pneumonia bacteria Results expected Jan 2027 (estimated)
- New combo shot study: could VAX-31 plus flu vaccine be a Game-Changer for seniors? Results expected Mar 2027 (estimated)
- New pneumonia vaccine VAX-31 aims to boost protection in older adults Results expected Mar 2027 (estimated)